title: Atypical severe central serous chorioretinopathy in a patient with systemic lupus erythematosus improved with a rapid reduction in glucocorticoid.
abstract: A 36-year-old woman was diagnosed with systemic lupus erythematosus (SLE). Seven days after beginning glucocorticoid treatment, she developed reduced visual acuity, and atypical severe central serous chorioretinopathy (CSC) was confirmed. Since glucocorticoid use is an important risk factor for CSC, the PSL was reduced, tacrolimus was added, and the visual acuity improved rapidly. Reduction in glucocorticoid combined with the use of immunosuppressive agents is one option for preventing a deterioration in atypical severe CSC while still controlling SLE.
authors.affiliation: Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuoku, Niigata, Niigata, 951-8510, Japan. hiroe-212@umin.ac.jp
authors.forename: Hiroe
authors.initials: H
authors.lastname: Sato
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ito
authors.forename: Shingo
authors.initials: S
authors.lastname: Nagai
authors.forename: Akira
authors.initials: A
authors.lastname: Murasawa
authors.forename: Yoko
authors.initials: Y
authors.lastname: Wada
authors.forename: Shuichi
authors.initials: S
authors.lastname: Murakami
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kuroda
authors.forename: Masaaki
authors.initials: M
authors.lastname: Nakano
authors.forename: Ichiei
authors.initials: I
authors.lastname: Narita
mesh_terms: D000328:Adult; D056833:Central Serous Chorioretinopathy / Q000139:chemically induced* / Q000150:complications / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008775:Methylprednisolone / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D020127:Recovery of Function; D016559:Tacrolimus / Q000627:therapeutic use; D016896:Treatment Outcome; D014786:Vision Disorders / Q000139:chemically induced* / Q000150:complications / Q000503:physiopathology; D014792:Visual Acuity / Q000502:physiology*
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D011239:Prednisolone; D016559:Tacrolimus; D008775:Methylprednisolone